What is Lexicon Pharmaceuticals Inc's earnings per share (EPS)?

Lexicon Pharmaceuticals Inc (LXRX) reported diluted earnings per share of $-0.14 for fiscal year 2025. This represents a 77.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lexicon Pharmaceuticals Inc Financials

LXRX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Lexicon Pharmaceuticals Inc (LXRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 48/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Lexicon Pharmaceuticals Inc has an operating margin of -98.2%, meaning the company retains $-98 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -634.2% the prior year.

Growth

100

Lexicon Pharmaceuticals Inc's revenue surged 60.2% year-over-year to $49.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Lexicon Pharmaceuticals Inc carries a low D/E ratio of 0.46, meaning only $0.46 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.88, Lexicon Pharmaceuticals Inc holds $4.88 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 98/100.

Cash Flow

While Lexicon Pharmaceuticals Inc generated -$67.9M in operating cash flow, capex of $0 consumed most of it, leaving -$67.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Lexicon Pharmaceuticals Inc generates a -46.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -137.3% the prior year.

Piotroski F-Score Neutral

4/9

Lexicon Pharmaceuticals Inc passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

1.35x

For every $1 of reported earnings, Lexicon Pharmaceuticals Inc generates $1.35 in operating cash flow (-$67.9M OCF vs -$50.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$49.8M

YoY+60.2%

5Y CAGR+15.7%

10Y CAGR-9.1%

Lexicon Pharmaceuticals Inc generated $49.8M in revenue in fiscal year 2025. This represents an increase of 60.2% from the prior year.

EBITDA

-$48.3M

YoY+75.4%

Lexicon Pharmaceuticals Inc's EBITDA was -$48.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 75.4% from the prior year.

Net Income

-$50.3M

YoY+74.9%

Lexicon Pharmaceuticals Inc reported -$50.3M in net income in fiscal year 2025. This represents an increase of 74.9% from the prior year.

EPS (Diluted)

$-0.14

YoY+77.8%

Lexicon Pharmaceuticals Inc earned $-0.14 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$67.9M

YoY+62.3%

Lexicon Pharmaceuticals Inc generated -$67.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 62.3% from the prior year.

Cash & Debt

$34.3M

YoY-48.5%

5Y CAGR-22.9%

10Y CAGR-16.3%

Lexicon Pharmaceuticals Inc held $34.3M in cash against $49.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

366M

YoY+0.8%

Lexicon Pharmaceuticals Inc had 366M shares outstanding in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

99.5%

YoY+1.4pp

5Y CAGR+7.5pp

10Y CAGR-0.5pp

Lexicon Pharmaceuticals Inc's gross margin was 99.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the prior year.

Operating Margin

-98.2%

YoY+536.0pp

5Y CAGR+101.0pp

10Y CAGR-99.3pp

Lexicon Pharmaceuticals Inc's operating margin was -98.2% in fiscal year 2025, reflecting core business profitability. This is up 536.0 percentage points from the prior year.

Net Margin

-101.1%

YoY+543.7pp

5Y CAGR+143.0pp

10Y CAGR-97.5pp

Lexicon Pharmaceuticals Inc's net profit margin was -101.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 543.7 percentage points from the prior year.

Return on Equity

-46.8%

YoY+90.5pp

5Y CAGR-9.4pp

10Y CAGR-45.2pp

Lexicon Pharmaceuticals Inc's ROE was -46.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 90.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$61.1M

YoY-27.7%

5Y CAGR-16.8%

10Y CAGR-4.3%

Lexicon Pharmaceuticals Inc invested $61.1M in research and development in fiscal year 2025. This represents a decrease of 27.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Lexicon Pharmaceuticals Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

LXRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$49.8M+60.2%	$31.1M+2481.5%	$1.2M+766.2%	$139K-53.4%	$298K-98.8%	$24.0M
Cost of Revenue	$274K-55.5%	$616K+624.7%	$85K	$0	$0-100.0%	$1.9M
Gross Profit	$49.5M+62.6%	$30.5M+2622.5%	$1.1M+705.0%	$139K-53.4%	$298K-98.6%	$22.1M
R&D Expenses	$61.1M-27.7%	$84.5M+43.5%	$58.9M+11.5%	$52.8M-4.1%	$55.0M-64.2%	$153.6M
SG&A Expenses	$37.3M-73.9%	$143.1M+25.5%	$114.0M+137.1%	$48.1M+48.7%	$32.3M-31.5%	$47.2M
Operating Income	-$48.9M+75.2%	-$197.1M-14.8%	-$171.8M-70.5%	-$100.8M-15.7%	-$87.1M-82.2%	-$47.8M
Interest Expense	N/A	N/A	N/A	$2.8M+246.6%	$802K-94.5%	$14.5M
Income Tax	N/A	$0	$0	$0	$0	N/A
Net Income	-$50.3M+74.9%	-$200.4M-13.1%	-$177.1M-73.7%	-$101.9M-16.2%	-$87.8M-49.8%	-$58.6M
EPS (Diluted)	$-0.14+77.8%	$-0.63+21.3%	$-0.80-29.0%	$-0.62-3.3%	$-0.60-13.2%	$-0.53

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$5.5M-61.3%	$14.2M-50.9%	$28.9M+2187.3%	$1.3M-95.2%	$26.6M+1417.4%	$1.8M+6.3%	$1.6M+45.8%	$1.1M
Cost of Revenue	$201K+1910.0%	$10K-69.7%	$33K+10.0%	$30K-91.4%	$348K+390.1%	$71K-57.2%	$166K+435.5%	$31K
Gross Profit	$5.3M-62.7%	$14.2M-50.8%	$28.8M+2240.3%	$1.2M-95.3%	$26.2M+1460.8%	$1.7M+13.4%	$1.5M+34.8%	$1.1M
R&D Expenses	$11.3M-39.7%	$18.8M+19.1%	$15.7M+2.9%	$15.3M-42.7%	$26.7M+3.5%	$25.8M+46.1%	$17.6M+22.8%	$14.4M
SG&A Expenses	$8.8M+15.2%	$7.6M-18.7%	$9.3M-19.5%	$11.6M-64.0%	$32.3M-18.5%	$39.6M+1.0%	$39.2M+22.2%	$32.1M
Operating Income	-$14.8M-21.3%	-$12.2M-426.2%	$3.7M+114.5%	-$25.7M+21.6%	-$32.7M+48.6%	-$63.7M-15.1%	-$55.4M-22.1%	-$45.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$15.5M-21.6%	-$12.8M-492.7%	$3.3M+112.9%	-$25.3M+25.1%	-$33.8M+47.9%	-$64.8M-21.3%	-$53.4M-10.4%	-$48.4M
EPS (Diluted)	N/A	$-0.04-500.0%	$0.01+114.3%	$-0.07	N/A	$-0.18-5.9%	$-0.17+15.0%	$-0.20

LXRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$185.0M-38.0%	$298.4M+30.1%	$229.4M+18.1%	$194.3M+41.9%	$136.9M-32.8%	$203.8M
Current Assets	$101.9M-58.6%	$246.2M+39.4%	$176.5M+25.3%	$140.9M+58.4%	$88.9M-43.6%	$157.7M
Cash & Equivalents	$34.3M-48.5%	$66.7M+196.7%	$22.5M-51.5%	$46.3M-27.7%	$64.1M-49.3%	$126.3M
Inventory	$281K+21.6%	$231K-39.4%	$381K	$0	N/A	$0
Accounts Receivable	$2.4M-31.4%	$3.5M+243.9%	$1.0M+3507.1%	$28K+100.0%	$14K-96.5%	$395K
Goodwill	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M
Total Liabilities	$77.4M-49.2%	$152.5M+11.8%	$136.3M+76.6%	$77.2M+231.0%	$23.3M-50.8%	$47.4M
Current Liabilities	$20.9M-53.9%	$45.2M+43.4%	$31.5M+36.1%	$23.2M+4.7%	$22.1M-52.7%	$46.8M
Long-Term Debt	$49.4M-50.7%	$100.3M+0.8%	$99.5M+104.8%	$48.6M	$0	$0
Total Equity	$107.5M-26.3%	$145.9M+56.8%	$93.1M-20.5%	$117.1M+3.1%	$113.6M-27.4%	$156.4M
Retained Earnings	-$2.0B-2.6%	-$2.0B-11.3%	-$1.8B-11.1%	-$1.6B-6.9%	-$1.5B-6.3%	-$1.4B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$185.0M-10.2%	$205.9M-8.7%	$225.6M-24.2%	$297.7M-0.3%	$298.4M-7.1%	$321.1M-14.0%	$373.4M-10.5%	$417.2M
Current Assets	$101.9M-16.8%	$122.5M-15.5%	$145.1M-41.0%	$245.8M-0.2%	$246.2M-8.3%	$268.6M-16.3%	$320.8M-12.0%	$364.6M
Cash & Equivalents	$34.3M-30.9%	$49.7M+132.4%	$21.4M-66.0%	$62.9M-5.7%	$66.7M+92.9%	$34.6M-3.0%	$35.6M-63.1%	$96.5M
Inventory	$281K+77.8%	$158K-6.0%	$168K-16.4%	$201K-13.0%	$231K-63.7%	$636K+8.7%	$585K+13.8%	$514K
Accounts Receivable	$2.4M+2.1%	$2.3M+6.9%	$2.2M-95.4%	$47.4M+1266.2%	$3.5M+20.0%	$2.9M+10.5%	$2.6M+71.7%	$1.5M
Goodwill	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M0.0%	$44.5M
Total Liabilities	$77.4M-9.7%	$85.8M-10.8%	$96.1M-44.9%	$174.6M+14.5%	$152.5M+6.9%	$142.6M+6.9%	$133.4M+3.9%	$128.4M
Current Liabilities	$20.9M-3.9%	$21.7M-37.7%	$34.8M-68.5%	$110.7M+144.6%	$45.2M+25.5%	$36.0M+29.3%	$27.9M+19.1%	$23.4M
Long-Term Debt	$49.4M-12.6%	$56.5M+0.7%	$56.1M-4.3%	$58.6M-41.5%	$100.3M+0.4%	$99.9M+0.4%	$99.5M-0.4%	$99.9M
Total Equity	$107.5M-10.5%	$120.2M-7.2%	$129.4M+5.2%	$123.0M-15.7%	$145.9M-18.2%	$178.5M-25.6%	$240.0M-16.9%	$288.9M
Retained Earnings	-$2.0B-0.8%	-$2.0B-0.6%	-$2.0B+0.2%	-$2.0B-1.3%	-$2.0B-1.7%	-$1.9B-3.5%	-$1.9B-2.9%	-$1.8B

LXRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$67.9M+62.0%	-$178.8M-10.4%	-$161.9M-82.2%	-$88.9M-2.1%	-$87.0M+39.1%	-$143.0M
Capital Expenditures	$0-100.0%	$1.0M+119.4%	$470K-64.6%	$1.3M+8.6%	$1.2M+1303.4%	$87K
Free Cash Flow	-$67.9M+62.3%	-$179.8M-10.7%	-$162.4M-80.1%	-$90.2M-2.2%	-$88.2M+38.3%	-$143.1M
Investing Cash Flow	$113.0M+834.9%	-$15.4M+69.2%	-$49.9M+29.7%	-$71.1M-3468.6%	$2.1M-99.4%	$380.8M
Financing Cash Flow	-$48.5M-120.3%	$238.3M+26.8%	$188.0M+32.2%	$142.2M+526.2%	$22.7M+115.4%	-$147.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$1.7M+110.0%	$824K-4.6%	$864K-67.7%	$2.7M+160.7%	$1.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$17.2M+27.7%	-$23.8M-240.3%	$17.0M+138.8%	-$43.8M-103.7%	-$21.5M+59.9%	-$53.6M-10.5%	-$48.5M+12.0%	-$55.1M
Capital Expenditures	$0	$0	N/A	N/A	$474K+54.4%	$307K+22.8%	$250K	$0
Free Cash Flow	-$17.2M+27.7%	-$23.8M	N/A	N/A	-$22.0M+59.3%	-$53.9M-10.5%	-$48.8M+11.5%	-$55.1M
Investing Cash Flow	$4.8M-90.7%	$52.1M+236.7%	$15.5M-61.8%	$40.6M-24.4%	$53.7M+0.4%	$53.5M+533.9%	-$12.3M+88.8%	-$110.2M
Financing Cash Flow	-$2.9M	$0+100.0%	-$45.0M-7767.1%	-$572K-450.0%	-$104K+88.6%	-$916K-6442.9%	-$14K-100.0%	$239.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$1.7M

LXRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	99.5%+1.4pp	98.0%+5.1pp	92.9%-7.1pp	100.0%0.0pp	100.0%+8.0pp	92.0%
Operating Margin	-98.2%+536.0pp	-634.2%+13630.7pp	-14264.9%+58224.3pp	-72489.2%-43264.4pp	-29224.8%-29025.6pp	-199.2%
Net Margin	-101.1%+543.7pp	-644.8%+14066.1pp	-14710.9%+58630.1pp	-73341.0%-43892.0pp	-29449.0%-29204.9pp	-244.1%
Return on Equity	-46.8%+90.5pp	-137.3%+52.9pp	-190.2%-103.2pp	-87.0%-9.8pp	-77.3%-39.8pp	-37.5%
Return on Assets	-27.2%+39.9pp	-67.2%+10.1pp	-77.2%-24.7pp	-52.5%+11.6pp	-64.1%-35.4pp	-28.7%
Current Ratio	4.88-0.6	5.44-0.2	5.60-0.5	6.08+2.1	4.02+0.6	3.37
Debt-to-Equity	0.46-0.2	0.69-0.4	1.07+0.7	0.41+0.4	0.000.0	0.00
FCF Margin	-136.2%+442.3pp	-578.5%+12907.1pp	-13485.6%+51389.9pp	-64875.5%-35265.5pp	-29610.1%-29013.9pp	-596.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	96.3%-3.6pp	99.9%+0.0pp	99.9%+2.3pp	97.6%-1.1pp	98.7%+2.7pp	95.9%+6.0pp	89.9%-7.3pp	97.3%
Operating Margin	-269.1%-183.2pp	-85.9%-98.9pp	12.9%+2047.7pp	-2034.8%-1911.5pp	-123.3%+3516.3pp	-3639.6%-278.7pp	-3360.9%+650.9pp	-4011.8%
Net Margin	-282.7%-192.7pp	-90.0%-101.3pp	11.3%+2015.6pp	-2004.4%-1877.2pp	-127.2%+3576.3pp	-3703.5%-459.5pp	-3244.0%+1038.9pp	-4282.9%
Return on Equity	-14.4%-3.8pp	-10.6%-13.1pp	2.5%+23.1pp	-20.6%+2.6pp	-23.1%+13.2pp	-36.3%-14.0pp	-22.3%-5.5pp	-16.8%
Return on Assets	-8.4%-2.2pp	-6.2%-7.6pp	1.4%+9.9pp	-8.5%+2.8pp	-11.3%+8.9pp	-20.2%-5.9pp	-14.3%-2.7pp	-11.6%
Current Ratio	4.88-0.8	5.64+1.5	4.16+1.9	2.22-3.2	5.44-2.0	7.45-4.1	11.51-4.1	15.58
Debt-to-Equity	0.46-0.0	0.47+0.0	0.43-0.0	0.48-0.2	0.69+0.1	0.56+0.1	0.41+0.1	0.35
FCF Margin	-313.7%-145.7pp	-168.1%	N/A	N/A	-82.7%+2998.8pp	-3081.5%-119.1pp	-2962.4%+1916.4pp	-4878.8%

Similar Companies

Aura Biosciences, Inc. AURA

$429.8M

Fulcrum Therapeutics FULC

$498.2M

Astria Therapeutics Inc ATXS

$718.1M

Solid Bioscience SLDB

$726.1M

Inhibrx Biosciences Inc INBX

$979.4M

Frequently Asked Questions

What is Lexicon Pharmaceuticals Inc's annual revenue?

Lexicon Pharmaceuticals Inc (LXRX) reported $49.8M in total revenue for fiscal year 2025. This represents a 60.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lexicon Pharmaceuticals Inc's revenue growing?

Lexicon Pharmaceuticals Inc (LXRX) revenue grew by 60.2% year-over-year, from $31.1M to $49.8M in fiscal year 2025.

Is Lexicon Pharmaceuticals Inc profitable?

No, Lexicon Pharmaceuticals Inc (LXRX) reported a net income of -$50.3M in fiscal year 2025, with a net profit margin of -101.1%.

What is Lexicon Pharmaceuticals Inc's EBITDA?

Lexicon Pharmaceuticals Inc (LXRX) had EBITDA of -$48.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Lexicon Pharmaceuticals Inc have?

As of fiscal year 2025, Lexicon Pharmaceuticals Inc (LXRX) had $34.3M in cash and equivalents against $49.4M in long-term debt.

What is Lexicon Pharmaceuticals Inc's gross margin?

Lexicon Pharmaceuticals Inc (LXRX) had a gross margin of 99.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lexicon Pharmaceuticals Inc's operating margin?

Lexicon Pharmaceuticals Inc (LXRX) had an operating margin of -98.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Lexicon Pharmaceuticals Inc's net profit margin?

Lexicon Pharmaceuticals Inc (LXRX) had a net profit margin of -101.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Lexicon Pharmaceuticals Inc's return on equity (ROE)?

Lexicon Pharmaceuticals Inc (LXRX) has a return on equity of -46.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lexicon Pharmaceuticals Inc's free cash flow?

Lexicon Pharmaceuticals Inc (LXRX) generated -$67.9M in free cash flow during fiscal year 2025. This represents a 62.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lexicon Pharmaceuticals Inc's operating cash flow?

Lexicon Pharmaceuticals Inc (LXRX) generated -$67.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lexicon Pharmaceuticals Inc's total assets?

Lexicon Pharmaceuticals Inc (LXRX) had $185.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lexicon Pharmaceuticals Inc's capital expenditures?

Lexicon Pharmaceuticals Inc (LXRX) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lexicon Pharmaceuticals Inc spend on research and development?

Lexicon Pharmaceuticals Inc (LXRX) invested $61.1M in research and development during fiscal year 2025.

How many shares does Lexicon Pharmaceuticals Inc have outstanding?

Lexicon Pharmaceuticals Inc (LXRX) had 366M shares outstanding as of fiscal year 2025.

What is Lexicon Pharmaceuticals Inc's current ratio?

Lexicon Pharmaceuticals Inc (LXRX) had a current ratio of 4.88 as of fiscal year 2025, which is generally considered healthy.

What is Lexicon Pharmaceuticals Inc's debt-to-equity ratio?

Lexicon Pharmaceuticals Inc (LXRX) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lexicon Pharmaceuticals Inc's return on assets (ROA)?

Lexicon Pharmaceuticals Inc (LXRX) had a return on assets of -27.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lexicon Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Lexicon Pharmaceuticals Inc (LXRX) had $34.3M in cash against an annual operating cash burn of $67.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lexicon Pharmaceuticals Inc's Piotroski F-Score?

Lexicon Pharmaceuticals Inc (LXRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lexicon Pharmaceuticals Inc's earnings high quality?

Lexicon Pharmaceuticals Inc (LXRX) has an earnings quality ratio of 1.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Lexicon Pharmaceuticals Inc?

Lexicon Pharmaceuticals Inc (LXRX) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.